Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Five Prime Therapeutics Inc    FPRX

FIVE PRIME THERAPEUTICS INC (FPRX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/10/2018 10/11/2018 10/12/2018 10/15/2018 10/16/2018 Date
12.82(c) 13.17(c) 13.1(c) 13.1(c) 13.83 Last
446 726 230 439 214 473 155 441 101 323 Volume
+0.16% +2.73% -0.53% 0.00% +5.57% Change
More quotes
Financials (USD)
Sales 2018 61,6 M
EBIT 2018 -133 M
Net income 2018 -136 M
Finance 2018 96,2 M
Yield 2018 -
Sales 2019 45,5 M
EBIT 2019 -171 M
Net income 2019 -168 M
Finance 2019 154 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 6,00x
EV / Sales2019 6,86x
Capitalization 466 M
More Financials
Company
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.The FPA008 is an antibody that inhibits colony stimulating factor-1,... 
More about the company
Surperformance© ratings of Five Prime Therapeutics In
Trading Rating : Investor Rating :
More Ratings
Latest news on FIVE PRIME THERAPEUTICS IN
03:10pFIVE PRIME THERAPEUTICS : Initiates Patient Dosing in The Dose Exploration Cohor..
BU
09/26FIVE PRIME THERAPEUTICS TO PRESENT A : Rare Disease & Oncology
BU
09/10FIVE PRIME THERAPEUTICS : Completes Phase 1 Safety Lead-In and Initiates Phase 3..
BU
08/30FIVE PRIME THERAPEUTICS : to Present at 2018 Wells Fargo Healthcare Conference
BU
08/09FIVE PRIME THERAPEUTICS : 2Q Earnings Snapshot
AQ
08/08FIVE PRIME THERAPEUTICS : Management's Discussion and Analysis of Financial Cond..
AQ
08/08FIVE PRIME THERAPEUTICS INC : Results of Operations and Financial Condition, Fin..
AQ
08/08FIVE PRIME THERAPEUTICS : Announces Second Quarter 2018 Financial Results
BU
07/26FIVE PRIME THERAPEUTICS : to Announce Second Quarter 2018 Financial Results and ..
BU
06/11FIVE PRIME THERAPEUTICS : to Present at Goldman Sachs 39th Annual Global Healthc..
BU
More news
Sector news : Bio Therapeutic Drugs
07:30aSanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
05:48pFive Prime starts dose exploration in early-stage study of FPA150 in solid tu.. 
10/11Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics,.. 
10/09Zacks: Brokerages Expect Five Prime Therapeutics Inc $FPRX Will Post Quarterl.. 
10/03$7.45 Million in Sales Expected for Five Prime Therapeutics Inc $FPRX This Qu.. 
10/03Five Prime Therapeutics $FPRX Cut to Sell at BidaskClub  
More tweets
Qtime:30
News from SeekingAlpha
11:48aFive Prime starts dose exploration in early-stage study of FPA150 in solid tu.. 
10/10CANCER RESEARCH HIGHLIGHT : Five Prime Moves To Prime Time With A New Phase 3 Tr.. 
10/03YOUR DAILY PHARMA SCOOP : Omeros Positive, Five Prime's Milestone 
10/01Dosing underway in late-stage study of Five Prime's bemarituzumab in gastric .. 
09/13Premarket analyst action - healthcare 
Chart FIVE PRIME THERAPEUTICS INC
Duration : Period :
Five Prime Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FIVE PRIME THERAPEUTICS IN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 31,3 $
Spread / Average Target 139%
EPS Revisions
Managers
NameTitle
Aron M. Knickerbocker President, Chief Executive Officer & Director
Lewis T. Williams Executive Chairman
Linda M. Rubinstein Chief Financial & Accounting Officer
Helen Collins Chief Medical Officer & Senior Vice President
Bryan Irving Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
FIVE PRIME THERAPEUTICS INC-40.24%466
GILEAD SCIENCES1.59%95 398
VERTEX PHARMACEUTICALS20.99%46 338
REGENERON PHARMACEUTICALS2.18%40 777
NEUROCRINE BIOSCIENCES, INC.41.84%10 086
SAREPTA THERAPEUTICS INC136.05%8 671